Well hope you're taking your first shot after yesterdays capital raise :--) UNCY is almost a walk in the park risk wise vs ICU .
ICU is burning thru cash as they struggle to get trial sites up and running and recruiting . But at least they have 100 enrolled so the interim analysis review is under way with data / opinion out my guess late Sept.
At least with UNCY all the clinical trials are complete and accepted . Issue is a 3rd party manufacturer ...which will be resolved ...question is when .
Market Data 
Markets 
AI
